Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.40 |
| ▸ | HTR2B | P41595 | 3/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HTR6 | P50406 | 6/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2851143 | 0.95 | HTR2C (0.42) | HTR2CHTR2BHTR2AHTR6DRD2 | |
| Hydrochloric Acid SCHEMBL7296037 | 0.94 | HTR6 (0.42) | HTR2CHTR2BHTR2AHTR6DRD2 | |
| Water SCHEMBL4080356 | 0.84 | HTR6 (0.47) | HTR2CHTR2BHTR2AHTR6DRD2 | |
| Caldaret SCHEMBL1650574 | 0.75 | ALDH1A1 (0.52) | HTR2CHTR2AHTR6HTR1A | |
| Caldaret SCHEMBL2853338 | 0.74 | ALDH1A1 (0.51) | HTR2CHTR2AHTR6HTR1A | |
| Caldaret SCHEMBL3139412 | 0.74 | ALDH1A1 (0.51) | HTR2CHTR2AHTR6HTR1A | |
| Caldaret SCHEMBL29711318 | 0.74 | ALDH1A1 (0.51) | HTR2CHTR2AHTR6HTR1A | |
| Caldaret SCHEMBL3135751 | 0.74 | ALDH1A1 (0.51) | HTR2CHTR2AHTR6HTR1A | |
| SCHEMBL24592918 | 0.74 | HTR2C (0.52) | HTR2CHTR2BHTR2AHTR6DRD2 | |
| SCHEMBL24451858 | 0.73 | HTR6 (0.46) | HTR2CHTR2BHTR2AHTR6DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080114000-A1 | Suppressor of excess accumulation of intracellular sodium ions | SATOU NAOYA | 2008-05-15 | — | — | US | claimed |
| US-20070270409-A1 | Medicament for Preventing and/or Treating Ischemic Cardiovascular Disease | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-22 | — | — | US | claimed |
| EP-1723955-A1 | MEDICINE FOR PREVENTION AND/OR TREATMENT OF ISCHEMIC CIRCULATORY DISEASE | Mitsubishi Pharma Corporation (JP) | 2006-11-22 | — | — | EP | claimed |
| US-20060167013-A1 | Inhibitors for excessive accumulation of sodium ion in cells | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-07-27 | — | — | US | claimed |
| US-20050124632-A1 | Remedies and/or preventives for diabetic ischemic heart diseases | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-06-09 | — | — | US | claimed |
| US-20050004139-A1 | Pharmaceutical preparations containing aminobenzene-sulfonic acid derivatives as the active ingredient | MITSUBISHI PHARMA CORPORATION (JP) | 2005-01-06 | — | — | US | claimed |
| US-20040259861-A1 | Medicament inhibiting sodium/calcium exchange system | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-12-23 | — | — | US | claimed |
| EP-1249245-B1 | REMEDIES AND/OR PREVENTIVES FOR NERVOUS SYSTEM DISORDERS | MITSUBISHI PHARMA CORP (JP) | 2004-12-15 | — | — | EP | claimed |
| EP-1419775-A1 | PHARMACEUTICAL PREPARATIONS CONTAINING AMINOBENZENE-SULFONIC ACID DERIVATIVES AS THE ACTIVE INGREDIENT | Mitsubishi Pharma Corporation (JP) | 2004-05-19 | — | — | EP | claimed |
| EP-1409080-A1 | MEDICAMENT INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM | Mitsubishi Pharma Corporation (JP) | 2004-04-21 | — | — | EP | claimed |
| EP-1374868-A1 | REMEDIES AND/OR PREVENTIVES FOR DIABETIC ISCHEMIC HEART DISEASES | Mitsubishi Pharma Corporation (JP) | 2004-01-02 | — | — | EP | claimed |
| US-20030114427-A1 | Remedies and/or preventives for nervous system disorders | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2003-06-19 | — | — | US | claimed |
| WO-2003009897-A1 | MEDICAMENT INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM | MITSUBISHI PHARMA CORPORATION (JP) | 2003-02-06 | — | — | WO | claimed |
| EP-1249245-A1 | REMEDIES AND/OR PREVENTIVES FOR NERVOUS SYSTEM DISORDERS | Mitsubishi Pharma Corporation (JP) | 2002-10-16 | — | — | EP | claimed |
| EP-0390654-B1 | Aminobenzenesulfonic acid derivative | MITSUBISHI CHEM IND (JP) | 1994-11-09 | — | — | EP | claimed |
| US-5053409-A | Calcium chanel blockers, antiischemic agent | MITSUBISHI KASEI CORPORATION (JP) | 1991-10-01 | — | — | US | claimed |
| EP-0390654-A1 | Aminobenzenesulfonic acid derivative | Mitsubishi Chemical Corporation (JP) | 1990-10-03 | — | — | EP | claimed |
| US-7652017-B2 | Remedies and/or preventives for nervous system disorders | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-01-26 | — | — | US | disclosed |
| US-5053409-A | Calcium chanel blockers, antiischemic agent | MITSUBISHI KASEI CORPORATION (JP) | 1991-10-01 | — | — | US | disclosed |
| EP-0390654-A1 | Aminobenzenesulfonic acid derivative | Mitsubishi Chemical Corporation (JP) | 1990-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259861-A1 | Medicament inhibiting sodium/calcium exchange system | ATP2A1, ATP2A3, ATP2A2 | HTR2C 2298/4885HTR2B 3012/4885HTR2A 2800/4885 |
| US-20070270409-A1 | Medicament for Preventing and/or Treating Ischemic Cardiovascular Disease | FABP3, TNNI3, TNNT2 | HTR2C 4319/4885HTR2B 2486/4885HTR2A 4191/4885 |
| US-20050124632-A1 | Remedies and/or preventives for diabetic ischemic heart diseases | SLC5A1, FABP3, IAPP | HTR2C 4286/4885HTR2B 1786/4885HTR2A 3530/4885 |
| US-20080114000-A1 | Suppressor of excess accumulation of intracellular sodium ions | ATP2A1, ATP2A2, ATP2A3 | HTR2C 4807/4885HTR2B 4524/4885HTR2A 4437/4885 |
| US-20050004139-A1 | Pharmaceutical preparations containing aminobenzene-sulfonic acid derivatives as the active ingredient | SI, NPPA, ATP6V1B1 | HTR2C 2011/4885HTR2B 152/4885HTR2A 1272/4885 |
| US-20030114427-A1 | Remedies and/or preventives for nervous system disorders | CHERP, ATP2A1, ATP2A3 | HTR2C 3625/4885HTR2B 3885/4885HTR2A 1959/4885 |
| US-20060167013-A1 | Inhibitors for excessive accumulation of sodium ion in cells | TNNI3, ATP2A1, SLC8B1 | HTR2C 4839/4885HTR2B 4429/4885HTR2A 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.